Genome-wide association studies (GWAS) indicate that ANRIL is a risk locus for diseases such as melanoma, basal cell carcinoma, nasopharyngeal carcinoma, leukaemia, glioma and breast cancer and that it is associated with prostate cancer, gastric cancer and pancreatic cancer [9–11]. The gene discussed is CDKN2B-AS1; the disease is melanoma.